Gary N. Schwartz
Research Subjects
Gary N. Schwartz has a total of 85 co-authors. Here are the top co-authors by number of shared publications:
- Todd W. Miller
Department of Molecular & Systems Biology, Norris Cotton Cancer Center, Geisel School of Medicine at Dartmouth, Lebanon, NH, USA
118 shared publications - Eugene Demidenko
Dartmouth College
116 shared publications - Fred Kolling
Dartmouth College
116 shared publications - Jonathan D. Marotti
Department of Pathology, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire
116 shared publications - Shannon Margaret Soucy
Department of Biomedical Data Science, Geisel School of Medicine, Hanover, NH, 03755, USA
116 shared publications - Abigail E. Goen
Biology Program, University of New Hampshire, Manchester, New Hampshire, USA
90 shared publications
Latest Publications
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Estrogen Therapy Induces Receptor-Dependent DNA Damage Enhanced by PARP Inhibition in ER+ Breast Cancer
Supplementary Figure S1- E2 induces changes in overlapping sets of genes in HCC-1428 and HCC-1428/LTED cells.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Estrogen Therapy Induces Receptor-Dependent DNA Damage Enhanced by PARP Inhibition in ER+ Breast Cancer
Supplementary Figure S1- E2 induces changes in overlapping sets of genes in HCC-1428 and HCC-1428/LTED cells.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S13 from Estrogen Therapy Induces Receptor-Dependent DNA Damage Enhanced by PARP Inhibition in ER+ Breast Cancer
Supplementary Figure S13- E2 and olaparib combine to increase R-loop formation.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S13 from Estrogen Therapy Induces Receptor-Dependent DNA Damage Enhanced by PARP Inhibition in ER+ Breast Cancer
Supplementary Figure S13- E2 and olaparib combine to increase R-loop formation.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from Estrogen Therapy Induces Receptor-Dependent DNA Damage Enhanced by PARP Inhibition in ER+ Breast Cancer
Supplementary Figure S5- ER-negative BT-20 cells do not exhibit increased DNA damage upon E2 treatment, while MCF-7/LTED show weak response.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from Estrogen Therapy Induces Receptor-Dependent DNA Damage Enhanced by PARP Inhibition in ER+ Breast Cancer
Supplementary Figure S5- ER-negative BT-20 cells do not exhibit increased DNA damage upon E2 treatment, while MCF-7/LTED show weak response.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S14 from Estrogen Therapy Induces Receptor-Dependent DNA Damage Enhanced by PARP Inhibition in ER+ Breast Cancer
Supplementary Figure S14- Individual growth curves of tumors from mice treated ± E2 and/or olaparib.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S14 from Estrogen Therapy Induces Receptor-Dependent DNA Damage Enhanced by PARP Inhibition in ER+ Breast Cancer
Supplementary Figure S14- Individual growth curves of tumors from mice treated ± E2 and/or olaparib.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Estrogen Therapy Induces Receptor-Dependent DNA Damage Enhanced by PARP Inhibition in ER+ Breast Cancer
Supplementary Figure S2- E2 induces DNA damage in LTED and ER-overexpressing cells.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Estrogen Therapy Induces Receptor-Dependent DNA Damage Enhanced by PARP Inhibition in ER+ Breast Cancer
Supplementary Figure S2- E2 induces DNA damage in LTED and ER-overexpressing cells.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S7 from Estrogen Therapy Induces Receptor-Dependent DNA Damage Enhanced by PARP Inhibition in ER+ Breast Cancer
Supplementary Figure S7- Single-channel fluorescence images of tumors from patients treated with E2.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S7 from Estrogen Therapy Induces Receptor-Dependent DNA Damage Enhanced by PARP Inhibition in ER+ Breast Cancer
Supplementary Figure S7- Single-channel fluorescence images of tumors from patients treated with E2.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from Estrogen Therapy Induces Receptor-Dependent DNA Damage Enhanced by PARP Inhibition in ER+ Breast Cancer
Histology of baseline human tumors.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from Estrogen Therapy Induces Receptor-Dependent DNA Damage Enhanced by PARP Inhibition in ER+ Breast Cancer
Histology of baseline human tumors.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S15 from Estrogen Therapy Induces Receptor-Dependent DNA Damage Enhanced by PARP Inhibition in ER+ Breast Cancer
Supplementary Figure S15- Individual growth curves of WHIM16 tumors from mice treated with a second cycle of E2 ± olaparib.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S15 from Estrogen Therapy Induces Receptor-Dependent DNA Damage Enhanced by PARP Inhibition in ER+ Breast Cancer
Supplementary Figure S15- Individual growth curves of WHIM16 tumors from mice treated with a second cycle of E2 ± olaparib.